Epirubicin exhibits potent anti-tumor activity in an animal model of malignant glioma when administered via controlled-release polymers.
Epirubicin (EPI) has strong cytotoxic activity that makes it a potential candidate for the treatment of malignant gliomas. To minimize toxicity and increase CNS penetration, EPI was incorporated into biodegradable polymers, and its in vitro and in vivo properties were studied. 9L, F98, C6, U251, and EMT-6 cell lines were treated with EPI in vitro and cell viability was measured. Toxicity of EPI/polycarboxyphenoxypropane-sebacic-acid (pCPP:SA) polymers was tested in vivo using F344 rats intracranially implanted with EPI polymers (2-50% by weight). The efficacy of 50% EPI:pCPP:SA polymers was determined in F344 rats intracranially challenged with 9L and treated either simultaneously or 5 days after tumor implantation. The efficacy of 50% EPI:pCCP:SA polymers administered on Day 5 in combination with oral TMZ was determined in rats intracranially challenged with 9L gliosarcoma. EPI was cytotoxic in all cell lines used in vitro. Intracranial implantation of the EPI polymers in rats generated neither local nor systemic toxicity. Animals receiving intracranial EPI on Day 5 had 50% long-term survivors (LTS), which was superior to local EPI delivered on Day 0 (LTS = 12.5%). Animals receiving intracranial EPI in combination with oral TMZ had 75% LTS whereas no other group had LTS. In those EPI treated animals that died before the controls there was evidence of intracranial hemorrhage. Systemic epirubicin resulted in high toxicity levels and early deaths in all the experiments. EPI polymers, alone or in combination with oral TMZ, is an effective therapeutic modality against experimental 9L gliosarcoma.
Recinos
Violette Renard
VR
Hunterian Neurosurgical Research Laboratory, Department of Neurosurgery, The Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA.
Bekelis
Kimon
K
Ziegler
Shira G
SG
Vick
Ditty
D
Hertig
Samuel
S
Tyler
Betty M
BM
Li
Khan W
KW
Kosztowski
Thomas
T
Legnani
Federico G
FG
Brem
Henry
H
Olivi
Alessandro
A
D000818:Animals; D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage* / Q000494:pharmacology; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects; D004195:Disease Models, Animal; D004305:Dose-Response Relationship, Drug; D004333:Drug Administration Routes; D016503:Drug Delivery Systems / Q000379:methods; D015251:Epirubicin / Q000008:administration & dosage* / Q000494:pharmacology; D005260:Female; D005910:Glioma / Q000188:drug therapy*; D006801:Humans; D011108:Polymers / Q000008:administration & dosage* / Q000494:pharmacology; D051381:Rats; D011916:Rats, Inbred F344; D013778:Tetrazolium Salts; D013844:Thiazoles; D013997:Time Factors
D000903:Antibiotics, Antineoplastic; D011108:Polymers; D013778:Tetrazolium Salts; D013844:Thiazoles; D015251:Epirubicin; C022616:thiazolyl blue
Biochemistry. 1987 Jun 30;26(13):3776-81
2820475
J Clin Oncol. 2006 Jun 20;24(18):2903-9
16782930
Ann Oncol. 2004 Oct;15(10):1517-26
15367413
J Immunol Methods. 1983 Dec 16;65(1-2):55-63
6606682
Neuro Oncol. 2003 Apr;5(2):79-88
12672279
Science. 1982 Jul 16;217(4556):248-50
7089561
J Neurooncol. 1995 Nov;26(2):111-23
8787853
J Neurosurg. 2009 Mar;110(3):583-8
19046047
Ann Surg Oncol. 2008 Oct;15(10):2887-93
18636295
Lancet. 1995 Apr 22;345(8956):1008-12
7723496
Gan To Kagaku Ryoho. 2006 Mar;33(3):318-23
16531711
Neurosurgery. 1997 Jul;41(1):44-8; discussion 48-9
9218294
Anticancer Res. 2006 Jan-Feb;26(1B):581-4
16739324
J Natl Compr Canc Netw. 2005 Sep;3(5):721-8
16194460
Pharmacol Ther. 1987;32(2):89-106
3037573
Biochem Pharmacol. 1989 Jan 1;38(1):167-72
2910297
Expert Rev Neurother. 2003 Jul;3(4):533-46
19810937
Anticancer Drugs. 2007 Jul;18(6):621-32
17762390
Curr Pharm Des. 2004;10(12):1341-53
15134485
Neuro Oncol. 2001 Oct;3(4):246-50
11584894
Semin Oncol. 2006 Jun;33(3 Suppl 8):S15-21
16781285
Brain. 1989 Apr;112 ( Pt 2):457-69
2706439
Anticancer Res. 2005 Nov-Dec;25(6B):3825-31
16312042
J Clin Oncol. 2002 Mar 1;20(5):1375-82
11870182
Cancer Res. 2005 Dec 15;65(24):11631-8
16357174
Acta Neurochir (Wien). 2006 Mar;148(3):269-75; discussion 275
16482400
Biochem Pharmacol. 1989 Nov 15;38(22):4069-74
2597184
N Engl J Med. 2005 Mar 10;352(10):987-96
15758009
Cancer J. 2003 May-Jun;9(3):149-56
12952300
JAMA. 2005 Feb 2;293(5):557-64
15687310